Bridging the gap: Multi-stakeholder perspectives of molecular diagnostics in oncology.

ABSTRACT: Molecular diagnostics has revolutionized cancer management, enabling the identification of diagnostic, prognostic, and predictive biomarkers. Despite advancements in technologies such as whole genome sequencing, their translation into clinical practice remains challenging due to insufficiently demonstrated clinical utility. This study identifies unmet clinical needs and requirements for innovative molecular technologies in oncology through interviews (n = 22) and an online survey (n = 116), gathering insights from hospital professionals, industry representatives, and health policy and quality assessment experts. Our findings emphasize the increasing importance of liquid biopsies (LBx), particularly plasma-based assays. Key unmet needs in this area include therapy response monitoring, minim

SUBMITTER: Arnouts J 

PROVIDER: S-EPMC12936412 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature